Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,000 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This trade represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Price Performance

Shares of Celcuity stock opened at $112.63 on Friday. The business has a fifty day simple moving average of $109.90 and a 200 day simple moving average of $92.66. The stock has a market cap of $5.44 billion, a PE ratio of -29.72 and a beta of 0.41. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $120.32.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.09. Research analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Hedge Funds Weigh In On Celcuity

Several institutional investors and hedge funds have recently modified their holdings of CELC. Creative Planning bought a new stake in Celcuity during the 2nd quarter worth approximately $177,000. Intech Investment Management LLC lifted its stake in Celcuity by 5.2% in the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after buying an additional 734 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after buying an additional 503 shares during the period. XTX Topco Ltd bought a new stake in shares of Celcuity during the second quarter worth $169,000. Finally, Saturn V Capital Management LP increased its position in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after acquiring an additional 91,843 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CELC has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 target price on shares of Celcuity in a research note on Thursday, March 26th. Wolfe Research reiterated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Wall Street Zen raised shares of Celcuity from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Wells Fargo & Company initiated coverage on shares of Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $109.88.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.